Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364597 · ClinicalTrials.gov registry record · Phase 3
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 257
- Enrollment target
NCT01364597 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 257 participants.
The verdict
NCT01364597, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 257 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
Interventions
- DRUG Brivaracetam (BRV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2011-08-01 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01364597
The ClinicalTrials.gov registry entry for NCT01364597 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam (BRV) is the first listed.
NCT01364597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01364597 about?
NCT01364597 is a clinical study titled "Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy". This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
What is the current status of trial NCT01364597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 257 participants. The study started on 2011-08-01. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT01364597?
The interventions under investigation include: Brivaracetam (BRV) (DRUG).
Who is sponsoring clinical trial NCT01364597?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.